Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Thermo Fisher Scientific    TMO

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : New, Versatile High-Resolution Mass Spectrometer Expands Market-leading Thermo Scientific Orbitrap Platform

share with twitter share with LinkedIn share with facebook
05/27/2020 | 09:46am EDT

SAN JOSE - A new generation, high resolution mass spectrometer (MS) is designed to give proteomics, metabolomics, biopharmaceutical characterization and small-molecule scientists the analytical performance required for research and high-throughput analyses.

The new system will help drive discovery and identification with increased accuracy for confident scale-up while operational simplicity and speed streamline time to results.

The Thermo Scientific Orbitrap Exploris 240 mass spectrometer expands the proven Orbitrap Exploris platform and delivers mass accuracy, sensitivity and resolving power across a wide dynamic range. With new-generation system architecture and instrument control software, the system provides simple yet powerful data acquisition capabilities, addressing the most demanding analytical challenges for small- and large-molecule applications. The system offers positive/negative mode switching for comprehensive sample coverage, fast scan speeds and functionalities including Thermo Scientific AcquireX intelligent data acquisition workflow that enable greater automation.

'Scientists are seeking technologies that can streamline and speed proteomics studies to clinical applications, reduce time to market for candidate biotherapeutics and address the growing challenge of characterizing novel chemical entities in small-molecule studies,' said Iain Mylchreest, vice president, research and development, analytical instruments, Thermo Fisher Scientific. 'As part of our expanded portfolio of new-generation instruments, the Orbitrap Exploris 240 mass spectrometer delivers the high performance and versatility needed to drive productivity across multiple applications.'

Dr. Timothy Garrett, associate professor, department of pathology, immunology and laboratory medicine, co-director of the Southeast Center for Integrated Metabolomics, University of Florida, said, 'Using the Orbitrap Exploris 240 mass spectrometer has been extremely user friendly, with one-click calibration and method templates for fast instrument setup. The system reproducibility in mass accuracy and peak integrated area over several sample batches and several days of acquisition has been impressive. This is very important for our large-scale metabolomics projects enabling minimum post-acquisition data manipulation to yield high quality results.'

The Thermo Scientific Orbitrap Exploris portfolio of high-resolution, accurate-mass (HRAM) systems, which launched in 2019 with the Thermo Scientific Orbitrap Exploris 480 mass spectrometer, now includes two new, highly capable instruments, the Thermo Scientific Orbitrap Exploris 240 and Thermo Scientific Orbitrap Exploris 120 mass spectrometer, allowing customers to easily transfer knowledge and methods from research and discovery to routine testing. The Orbitrap Exploris 480 and 240 mass spectrometers are fully compatible with the Thermo Scientific FAIMS Pro interface to achieve enhanced identification of proteins and peptides. Improved quantitative performance for translational proteomics and high-throughput studies will enable researchers to accelerate the translation of discoveries into clinical applications.

Dr. Jonathan Bones, principal investigator, National Institute for Bioprocessing Research and Training, said, 'The Orbitrap Exploris 240 mass spectrometer is a reliable and flexible solution for high-performance biopharmaceutical characterization and achieves impressive sensitivity for native MS analyses. With the Thermo Scientific Vanquish Duo UHPLC systems running in tandem mode, there is no more waiting during column equilibration; the mass spectrometer constantly acquires valuable data with all the available features of the Thermo Scientific Chromeleon Chromatography Data System (CDS) software. The system is a must-have instrument for analytical and characterization laboratories supporting biopharmaceutical development and manufacture.'

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Contact:

Laura Bright

Tel: +1 562-335-8318

Email: laura.bright@thermofisher.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
Latest news on THERMO FISHER SCIENTIFIC
07/09THERMO FISHER SCIENTIFIC : Declares Quarterly Dividend
PR
07/07THERMO FISHER SCIENTIFIC : Provides Update to Second Quarter Outlook and Will Ho..
AQ
07/06Thermo Fisher, Uber rise; Bellus, Dominion fall
AQ
07/06THERMO FISHER SCIENTIFIC : Says 2Q Sales Boosted by Pandemic Response
DJ
07/06THERMO FISHER SCIENTIFIC INC. : Results of Operations and Financial Condition, F..
AQ
07/06THERMO FISHER SCIENTIFIC : Provides Update to Second Quarter Outlook and Will Ho..
PR
07/02THERMO FISHER SCIENTIFIC : Launches New MAS Omni Infectious Disease Quality Cont..
AQ
06/23THERMO FISHER SCIENTIFIC : Schrodinger in Collaboration with Thermo Fisher Scien..
DJ
06/17THERMO FISHER SCIENTIFIC : iSPA Workflow Helps Pharmaceutical Companies Bring Ne..
AQ
06/12THERMO FISHER SCIENTIFIC : Ex-dividend day for
FA
More news
Financials (USD)
Sales 2020 27 701 M - -
Net income 2020 3 528 M - -
Net Debt 2020 12 387 M - -
P/E ratio 2020 43,1x
Yield 2020 0,22%
Capitalization 151 B 151 B -
EV / Sales 2019
EV / Sales 2020 5,90x
Nbr of Employees 75 000
Free-Float 90,5%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 378,12 $
Last Close Price 382,57 $
Spread / Highest target 12,4%
Spread / Average Target -1,16%
Spread / Lowest Target -29,2%
EPS Revisions
Managers
NameTitle
Marc N. Casper Chairman, President & Chief Executive Officer
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Scott M. Sperling Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERMO FISHER SCIENTIFIC17.76%151 096
DANAHER CORPORATION19.67%129 858
INTUITIVE SURGICAL, INC.-2.82%67 157
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.75.19%55 340
ILLUMINA, INC.12.32%54 427
BOSTON SCIENTIFIC CORPORATION-23.71%49 416